Discontinued Product

(RS)-PPG (Cat. No. 1220) has been withdrawn from sale for commercial reasons.
Description: Potent and selective mGlu8 agonist
Chemical Name: (RS)-4-Phosphonophenylglycine
Citations (1)
Literature (4)

Biological Activity for (RS)-PPG

(RS)-PPG is a potent and selective group III metabotropic glutamate receptor agonist, with approximately 25-fold preference for hmGlu8; anticonvulsant and neuroprotective in vivo.

Technical Data for (RS)-PPG

M. Wt 231.14
Formula C8H10NO5P
Storage Store at RT
CAS Number 120667-15-4
PubChem ID 4545574
Smiles NC(C(O)=O)C1=CC=C(P(O)(O)=O)C=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for (RS)-PPG

Certificate of Analysis / Product Datasheet
Select another batch:

References for (RS)-PPG

References are publications that support the biological activity of the product.

Bigge et al (1989) Exploration of phenyl-spaced 2-amino-(5,9)-phosphonoalkanoic acids as competitive N-MthD.-aspartic acid antagonists. J.Med.Chem. 32 1580 PMID: 2544728

Gasparini et al (1999) (R,S)-4-Phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo. J.Pharmacol.Exp.Ther. 289 1678 PMID: 10336568

Flor et al (1998) Neuroprotection in vitro and in vivo by (R,S)-PPG, a potent and selective group III metabotropic glutamate receptor agonist. Soc.Neurosci.Abstr. 24 431.11

View Related Products by Product Action

View all Glutamate (Metabotropic) Group III Receptor Agonists

Keywords: (RS)-PPG, (RS)-PPG supplier, Potent, selective, mGlu8, mGluR8, agonist, Group, III, Receptors, Glutamate, Metabotropic, (Metabotropic), 1220, Tocris Bioscience

1 Citation for (RS)-PPG

Citations are publications that use Tocris products. Selected citations for (RS)-PPG include:

Kammermeier (2015) Constitutive activity of metabotropic glutamate receptor 7. Neuropharmacology 16 17 PMID: 25881041

Reviews for (RS)-PPG

There are currently no reviews for this product. Be the first to review (RS)-PPG and earn rewards!

Have you used (RS)-PPG?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Metabotropic Glutamate Receptors Scientific Review

Metabotropic Glutamate Receptors Scientific Review

Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Learning & Memory Poster

Learning & Memory Poster

Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.